Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IDEA-FAST

Financiado

Cerrado

Identifying Digital Endpoints to Assess FAtigue Sleep and acTivities in daily l...

Identifying Digital Endpoints to Assess FAtigue Sleep and acTivities in daily living in Neurodegenerative disorders and Immune mediated inflammatory diseases Fatigue and sleep disturbances are two common and disabling symptoms that affect patients with neurodegenerative disorders (NDD) and immune-mediated inflammatory diseases (IMID). These symptoms are major predictors of poor quality... ver más

30/04/2026

UNEW

42M€

Presupuesto del proyecto: 42M€

Líder del proyecto

UNIVERSITY OF NEWCASTLE UPON TYNE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 58 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-12-18

IMI2-2018-15-06: Digital endpoints in neurodegenerat...

I+D

Cerrada hace 6 años

0% 50% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

58 Participantes

UNEW

4.55M€ | Lider

ESMALGLASS

689.68K€ | Participante

JANSSEN PHARMACEUTICA NV

6.97M€ | Participante

UCC

N.D. | Participante

Proyectos interesantes

MS Fatigue_Therapy

Medical Technol...

Data Science

159K€ Cerrado

RHYTHM IN DEMENTIA

Medical Technol...

Data Science

2M€ Cerrado

DISCO

Medical Technol...

Data Science

500K€ En diseño

PredictND

Medical Technol...

Data Science

4M€ Cerrado

QFATIGUE

Medical Technol...

Data Science

45K€ Cerrado

MEMEMTUM

Medical Technol...

Data Science

71K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 76 meses Fecha Inicio: 2019-12-18
Fecha Fin: 2026-04-30

Líder del proyecto

UNIVERSITY OF NEWCASTLE UPON TYNE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 42M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Fatigue and sleep disturbances are two common and disabling symptoms that affect patients with neurodegenerative disorders (NDD) and immune-mediated inflammatory diseases (IMID). These symptoms are major predictors of poor quality of life and increased healthcare cost. Current questionnaire-based approaches to measure these symptoms have key limitations preventing them from being used as reliable endpoints in clinical trials to evaluate the effect of therapies. IDEA-FAST aims to address these issues by identifying novel digital endpoints for fatigue and sleep disturbances that will provide more objective, sensitive and reliable measures of the severity and impact of these symptoms in ecological settings. Such digital endpoints will not only help to gain insight into the underpinning mechanisms of fatigue and sleep disturbances, but will also vastly improve the efficiency of clinical trials, ultimately reducing the time and cost to bring new therapies to patients. To identify these digital endpoints, we will follow the recommendations of the Clinical Trials Transformation Initiative (CTTI). We will identify the characteristics that fatigue and sleep disturbances will have impact, then select the digital measures (endpoints) to quantify them, followed by choosing the appropriate digital device/technology accordingly. We will then perform a pilot study to prioritise a few of these candidate digital endpoints for validation. We will test the performance of these digital endpoints in two NDD and four IMID in a large longitudinal study during which extensive relevant clinical data will be collected. If these digital endpoints were validated, we will seek support from EMA/FDA for their qualification. Patient users’ perspective, ethical, data privacy, legal and other regulatory issues will be taken into consideration in all aspects of our proposal. The resultant digital biobank from the longitudinal study will become an invaluable resource for future exploitation.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores